TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25464260

Group type: EXPERIMENTAL
Intervention: Short-term antihypertensive treatment (median follow-up of 20 days)
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Top quartile of PWV
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Factors related to smaller BP decline
Number of subjects: 3056
Study: 23325372

Group type: EXPERIMENTAL
Intervention: aripiprazole + escitalopram
Number of subjects: 35

Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 35
Study: 21728080

Group type: EXPERIMENTAL
Intervention: AirWay Scope (AWS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both AWS and Macintosh laryngoscope
Number of subjects: 68
Study: 19126368

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No epidural steroid injection (Control)
Number of subjects: 0
Study: 17955651

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus acupoint-injection
Number of subjects: 78

Group type: COMPARATOR
Intervention: Electroacupuncture alone
Number of subjects: 78
Study: 16020985

Group type: EXPERIMENTAL
Intervention: oral administration of trimetazidine, prednisolone, and vitamin B complex
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: trimetazidine alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: prednisolone and vitamin B complex
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: intravenous piracetam and prednisolone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: further treatment with trimetazidine for a month
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: timely initiation of therapy within the first week following acoustic trauma
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: degree of hearing improvement after medication
Number of subjects: 108
Study: 11674925

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 4 weeks after a 2 week placebo period
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9476039

Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7889958

Group type: EXPERIMENTAL
Intervention: Cefprozil 20 mg/kg once daily
Number of subjects: 1597

Group type: EXPERIMENTAL
Intervention: Cefprozil twice daily
Number of subjects: 1597

Group type: EXPERIMENTAL
Intervention: Cefprozil once daily
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Penicillin three times a day
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Cefaclor three times a day
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate four times a day
Number of subjects: 1597
Study: 3312179

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 44
Study: 28815792

Group type: EXPERIMENTAL
Intervention: Farmed (legal) sea turtle products
Number of subjects: 560

Group type: COMPARATOR
Intervention: Wild-sourced (illegal) sea turtle products
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Consumer preferences
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Choice experiments
Number of subjects: 560
Study: 27323347

Group type: EXPERIMENTAL
Intervention: Zoledronate 4 mg i.v. for 5 years, administered every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 0
Study: 25939514

Group type: EXPERIMENTAL
Intervention: SNP rs5993891 in the ARVCF gene on chromosome 22q11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis across all studies
Number of subjects: 0
Study: 24121220

Group type: EXPERIMENTAL
Intervention: Bio-electro-magnetic-regulation treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined therapy (Bio-electro-magnetic-regulation treatment + Pentoxifylline infusions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21095135

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo drink (PLA)
Number of subjects: 9
Study: 18240145

Group type: EXPERIMENTAL
Intervention: HTI-286
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous castration plus HTI-286 therapy
Number of subjects: 0
Study: 16373903

Group type: EXPERIMENTAL
Intervention: Insulin analog
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regular insulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 14610014

Group type: EXPERIMENTAL
Intervention: Persistent atrial fibrillation (persistAF)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Successful cardioversion
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Direct current (DC) energy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HPCs from patients with AF
Number of subjects: 46
Study: 11221123

Group type: EXPERIMENTAL
Intervention: Improved STD case management using the syndromic approach at intervention health units.
Number of subjects: 8845

Group type: EXPERIMENTAL
Intervention: Intervention health units with improved STD services.
Number of subjects: 8845

Group type: EXPERIMENTAL
Intervention: Home visits to non-returners after treatment.
Number of subjects: 8845

Group type: EXPERIMENTAL
Intervention: Attendance at intervention health units.
Number of subjects: 8845

Group type: COMPARATOR
Intervention: Referral to higher levels of health care.
Number of subjects: 8845
Study: 8817142

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuit with reduced systemic heparinization (ACT > 250 s) (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with uncoated circuits and full heparin dose (ACT > 480 s) (n = 16)
Number of subjects: 33
Study: 1306211

Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1 muscarinic antagonist)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Biperiden (M1 muscarinic antagonist)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3873478

Group type: EXPERIMENTAL
Intervention: Timolol, 0.5% (T)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carteolol, 1% (C1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carteolol, 2% (C2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Balanced saline (S)
Number of subjects: 36
Study: 31661850

Group type: EXPERIMENTAL
Intervention: Treatment A: 140 mg of ZynamiteÂ®, 140 mg of quercetin, 147.7 mg of maltodextrin, and 420 mg of sunflower lecithin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treatment B: 140 mg of ZynamiteÂ®, 140 mg of quercetin, and 2126 mg of maltodextrin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment C: 2548 mg of maltodextrin (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ZynamiteÂ® with quercetin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polyphenols (ZynamiteÂ® and quercetin)
Number of subjects: 40
Study: 29808041

Group type: EXPERIMENTAL
Intervention: Tranexamic acid group (2gm of tranexamic acid diluted in 50ml of normal saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group (cardiac bath without tranexamic acid)
Number of subjects: 100
Study: 26787023

Group type: EXPERIMENTAL
Intervention: Power whitening gel (38% Hydrogen Peroxide)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tooth whitening pen (16% Carbamide Peroxide)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (artificial saliva)
Number of subjects: 45
Study: 25146349

Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non DHI group (control)
Number of subjects: 86
Study: 22137765

Group type: EXPERIMENTAL
Intervention: Self-help strategies (26 strategies assessed)
Number of subjects: 1326
Study: 19733931

Group type: EXPERIMENTAL
Intervention: Customized chemotherapy based on ERCC1 mRNA expression for patients with low levels of ERCC1 (docetaxel/cisplatin) and high levels of ERCC1 (docetaxel/gemcitabine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHRNA3 genotype (CT) in low genotypic group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm received docetaxel/cisplatin
Number of subjects: 0
Study: 18585496

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Unfractionated heparin plus routine use of GP IIb/IIIa inhibitors
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Bare-metal stents (BMSs)
Number of subjects: 3602
Study: 17012684

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with moderate level of transference interpretations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic psychotherapy with no transference interpretations
Number of subjects: 100
Study: 14618108

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - micronized estradiol: 1 mg/day, progesterone: 0.25 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11095120

Group type: EXPERIMENTAL
Intervention: Ketorolac-tobramycin combination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluorometholone-tobramycin combination
Number of subjects: 60
Study: 8821085

Group type: EXPERIMENTAL
Intervention: Drawing from memory (with or without forewarning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copy condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory conditions (drawing from memory)
Number of subjects: 0
Study: 1467386

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.35 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6369214

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 80
Study: 31735969

Group type: EXPERIMENTAL
Intervention: Self‐paced weight loss intervention
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Counselor‐initiated weight loss intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 204

Group type: COMPARATOR
Intervention: Participants with overweight
Number of subjects: 204
Study: 30240280

Group type: EXPERIMENTAL
Intervention: 40% ASiR at normal dose (NI 10-40%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40% ASiR at low dose (NI 20-40%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MBIR at low dose (NI 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MBIR
Number of subjects: 40
Study: 27763682

Group type: EXPERIMENTAL
Intervention: Opicapone (5, 15, and 30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Opicapone (5, 15, and 50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26750622

Group type: EXPERIMENTAL
Intervention: ARNI (LCZ696; sacubitril-valsartan)
Number of subjects: 8000
Study: 25074885

Group type: EXPERIMENTAL
Intervention: Cinnamon ointment, 2 mL every 12 h for 10 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo ointment, 2 mL every 12 h for 10 days
Number of subjects: 144
Study: 23211912

Group type: EXPERIMENTAL
Intervention: Wraparound video eyewear
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sunglasses (control)
Number of subjects: 128
Study: 19530978

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 17517342

Group type: EXPERIMENTAL
Intervention: Low serum levels of apolipoprotein A-I (< 103 mg/dL)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Serum levels of apolipoprotein A-I measured by immunoturbidimetry
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Clinical events during follow-up
Number of subjects: 117
Study: 15133010

Group type: EXPERIMENTAL
Intervention: FI(O2) 0.10 (hypoxia)
Number of subjects: 6

Group type: COMPARATOR
Intervention: FI(O2) 0.21 (normoxia)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: FI(O2) 1.00 (hyperoxia)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: End-exercise pH across treatments
Number of subjects: 6
Study: 11868527

Group type: EXPERIMENTAL
Intervention: Permanent magnetic field (induction 60 mT) treatment
Number of subjects: 0
Study: 9036306

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study: 7880762

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5-methoxypsoralen (5-MOP)
Number of subjects: 38
Study: 3068633

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 20
Study: 29576124

Group type: EXPERIMENTAL
Intervention: Median nerve block
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ulnar nerve block
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Radial nerve block
Number of subjects: 12

Group type: COMPARATOR
Intervention: All nerve blocks (median, ulnar, radial)
Number of subjects: 12
Study: 28500678

Group type: EXPERIMENTAL
Intervention: BGG492 150 mg t.i.d.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BGG492 100 mg t.i.d.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BGG492 (both doses) during open-label extension study
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BGG492 150 mg
Number of subjects: 93
Study: 26290435

Group type: EXPERIMENTAL
Intervention: Blisibimod (0.1, 0.3, 1, or 3 mg/kg SC or 1, 3, or 6 mg/kg IV) - single dose
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Blisibimod (0.3, 1, or 3 mg/kg SC or 6 mg/kg IV) - four weekly doses
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 23104705

Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Roux-en-Y (RY)
Number of subjects: 332
Study: 22010227

Group type: EXPERIMENTAL
Intervention: D1 agonist
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D2 agonist
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline controls
Number of subjects: 36
Study: 19895679

Group type: EXPERIMENTAL
Intervention: Modified CIMT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified BATRAC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment program (dose-matched)
Number of subjects: 60
Study: 16484701

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 582

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 582
Study: 12827350

Group type: EXPERIMENTAL
Intervention: Alcohol (256 g per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11034431

Group type: EXPERIMENTAL
Intervention: Moderate Resistance (MR = 5.9 kg for females and 10.5 kg for males)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Light Resistance (LR = 1.4 kg for males and females)
Number of subjects: 30
Study: 9012723

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study: 8450998

Group type: EXPERIMENTAL
Intervention: Low-dose apomorphine (0.01 mg/kg) SC
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3092934

Group type: EXPERIMENTAL
Intervention: Supportive female companions during labour
Number of subjects: 465

Group type: COMPARATOR
Intervention: Labour alone
Number of subjects: 465
Study: 31877910

Group type: EXPERIMENTAL
Intervention: Virtual reality exergame system (4 weeks, at least 2 extra sessions per week, average duration 44 min per session)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (traditional therapy only)
Number of subjects: 18
Study: 28157565

Group type: EXPERIMENTAL
Intervention: Variable Game Group (VGG) - exergames training delivered under variable practice schedule
Number of subjects: 111

Group type: COMPARATOR
Intervention: Repetitive Game Group (RGG) - exergames training delivered under repetitive practice schedule
Number of subjects: 111
Study: 25333245

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (PN) 450 mg per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (PN)
Number of subjects: 13
Study: 22945882

Group type: EXPERIMENTAL
Intervention: SAMITAL®
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21877927

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (EXE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No physical exercise (CON)
Number of subjects: 12
Study: 18457751

Group type: EXPERIMENTAL
Intervention: Walking intervention for 3 days a week for Group I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking intervention for 5 days a week for Group II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Walking interventions (both groups)
Number of subjects: 0
Study: 16705919

Group type: EXPERIMENTAL
Intervention: Surgical techniques for congenital heart diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up after heart surgery
Number of subjects: 0
Study: 14700335

Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 30

Group type: COMPARATOR
Intervention: Injectable resin modified glass ionomer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compomer
Number of subjects: 30
Study: 10960383

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 51
Study: 8792921

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with Parietaria extract
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 25
Study: 1599300

Group type: EXPERIMENTAL
Intervention: Gaviscon plus Carobel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cisapride (0.8 mg/kg/day)
Number of subjects: 50
Study: 6374058

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30317532

Group type: EXPERIMENTAL
Intervention: Real rTMS (2000 pulses, 20 Hz at 100% rMT for 10 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS (2000 pulses, 20 Hz at 100% rMT for 10 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 26
Study: 30004916

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BM-MNCs) injected intramuscularly at 40 locations of the calf muscle (500-700 mL harvested, 40 mL concentrated).
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (diluted blood) injected intramuscularly at 40 locations of the calf muscle.
Number of subjects: 54
Study: 26613203

Group type: EXPERIMENTAL
Intervention: PCBMT (4-session program adapted from mindfulness-based stress reduction)
Number of subjects: 62

Group type: COMPARATOR
Intervention: PC treatment as usual (control group)
Number of subjects: 62
Study: 25138064

Group type: EXPERIMENTAL
Intervention: Full-dose almonds (50-100 g/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Half-dose almonds with half-dose muffins
Number of subjects: 27

Group type: COMPARATOR
Intervention: Full-dose muffins
Number of subjects: 27
Study: 22762147

Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4‐day regimen (n= 56)
Number of subjects: 110

Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7‐day regimen (n= 54)
Number of subjects: 110
Study: 20085939

Group type: EXPERIMENTAL
Intervention: sorafenib 400 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 17333436

Group type: EXPERIMENTAL
Intervention: Duloxetine (placebo-controlled trial)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Patient assessments of severity
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: PGI‐I and CGI‐I
Number of subjects: 553
Study: 16279568

Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11870962

Group type: EXPERIMENTAL
Intervention: Preventive oral hygiene program (professional tooth cleaning, dental health information, and oral hygiene instruction) over a 6-month period
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preventive oral hygiene program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 11686668

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol treatment for 24 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with transdermal oestradiol and medroxyprogesterone for 6 weeks
Number of subjects: 20
Study: 9621291

Group type: EXPERIMENTAL
Intervention: Serum leptin levels in CRF patients
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Percentage of body fat (assessed from skinfold measurements)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: GFR
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Standardized leptin levels (leptin z-score)
Number of subjects: 134